MOTS-c Research Canada: Human Evidence Limits

What is MOTS-c, and has it been shown to work in people? MOTS-c is a 16-amino-acid mitochondrial-derived peptide. Foundational papers include cell experiments, interventions in mice and measurements of the body's own peptide after exercise in people. Those human measurements are not a clinical trial of administered MOTS-c.

This original FirstLabs editorial review was updated November 6, 2026. It is educational information, not medical advice, a dosing guide or a recommendation for personal use. FirstLabs catalogue materials are for laboratory research only, not human or veterinary use.

MOTS-c identity and mitochondrial origin

Lee and colleagues identified MOTS-c in 2015 as a peptide encoded within the mitochondrial 12S rRNA region. Their work linked it to metabolic regulation through folate and purine metabolism and AMPK-related signalling.

A pathway observation describes a biological mechanism. It does not establish improved health, fat loss, exercise performance or lifespan in people receiving an external product.

The 2015 foundational study: cells and mice

The Cell Metabolism paper combined cell experiments with mouse interventions. The authors reported protection against age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mice.

The model and intervention belong beside that result: these were not human obesity-treatment findings. Mouse metabolic responses cannot establish a safe or effective personal-use regimen.

The 2021 performance paper: separate mouse interventions from human exercise

Reynolds and colleagues reported physical-performance findings in young, middle-aged and old mice. Late-life intermittent treatment was associated with improved physical capacity and healthspan in mice. Healthspan describes functional findings in that experiment, not proof of human lifespan extension.

The paper separately examined exercise-associated changes in endogenous MOTS-c in human skeletal muscle and circulation. Endogenous means produced within the body. The participants' exercise response was not a trial giving people MOTS-c research vials.

What would establish human treatment evidence?

The two papers cited here do not establish clinical benefit or safety from administered MOTS-c in people. Stronger evidence would need controlled human studies of an identified formulation, appropriate comparators, prespecified clinical endpoints, adverse-event reporting and adequate follow-up.

Do not transfer findings from an analogue, a different peptide, exercise-induced production or a mouse intervention to an offered vial. This review does not establish Canadian drug authorization and provides no dosing or injection advice.

MOTS-c research questions

Is MOTS-c the same as SS-31?

No. MOTS-c is a mitochondrial-derived peptide; SS-31 is a synthetic tetrapeptide also known as elamipretide. Their identities, mechanisms and evidence differ.

Does exercise research prove an injected MOTS-c product works?

No. Measuring a body's own peptide after exercise does not test an external preparation.

Are 10mg and 20mg clinical study doses?

No. Here they identify separately labelled catalogue quantities for laboratory research, not personal-use instructions.

Laboratory documentation is a separate question

Evidence about MOTS-c in a clinical study does not establish that a FirstLabs vial is equivalent to the studied formulation. A certificate of analysis describes the submitted sample, not medical suitability or regulatory authorization. HPLC purity does not by itself establish quantity, sterility, endotoxin control or a match to current stock.

For laboratory records, verify exact identity and labelled size, analytical methods, measured quantity, sample identifiers and any available lot-to-stock documentation. A laboratory task ID is not automatically a manufacturing lot. Keep missing reports and adverse results visible rather than borrowing evidence from another size.

Compare the separate MOTS-c 10mg and MOTS-c 20mg catalogue records and their exact-size documentation. A 10mg report cannot verify a 20mg vial; missing documentation remains a gap.

Related reading: SS-31, elamipretide and regulatory limits and NAD+ versus NR and NMN. The cover is an illustrative cell model, not study imagery.

Read our COA verification checklist, published laboratory reports and Canadian regulation overview for these distinctions.

Primary sources and editorial scope

FirstLabs is a research-material supplier with a commercial interest in the compounds discussed, not a licensed pharmacy or an independent medical authority. Results belong to their original study populations, formulations and endpoints. No personal outcome, treatment protocol or authorization of catalogue products is implied.

MOTS-c Research: Mitochondrial Biology, Mouse Findings and Human Evidence Limits